SRTD Biotech

📂 Healthtech📍 Jülich🗓️ Founded: 2019

German biotech developing selectively expressed RNA for oncology, autoimmune disease and fibrosis.

Europe's most interesting startup stories. Every week.

No spam. Unsubscribe anytime.

Podcast Episode

🎙️ Deep Dive

Onodrim Industries, SRTD Biotech, T-Therapeutics — $300M for defence, €31.5M for RNA and $133M for bispecifics — Daily News November 9, 2026

Listen to the episode

About SRTD Biotech

SRTD Biotech is a biotech founded in 2019 in Jülich, Germany, by Chief Scientific Officer Bernd Hoffmann. It develops selectively expressed RNA (seRNA) constructs that switch on therapeutic mRNA only inside target cells by recognising their disease markers, together with lipid nanoparticles to reach organs such as the liver, lungs and brain and an RNA design platform based on bioinformatics and AI. On 9 November 2026 it closed an oversubscribed €31.5 million seed round led by Mérieux Equity Partners, co-led by NRW.BANK and Boehringer Ingelheim Venture Fund, with Lilly Ventures, HTGF and Anobis Asset; after the round it appointed Matthias Alder as CEO. The funds will take its still-preclinical pipeline to an Investigational New Drug filing.

The Story

Founded in Jülich in 2019 by biologist Bernd Hoffmann, now Chief Scientific Officer.

How SRTD Biotech works

Business Model

Development of proprietary drugs with possible licensing and partnership deals.

Products & Services

Key Products

  • seRNA platform
  • Fusogenic lipid nanoparticles

Core Use Cases

  • RNA therapies for oncology
  • RNA therapies for autoimmune disease
  • RNA therapies for fibrosis

Market & Clients

Geographic Presence

DE

How SRTD Biotech competes

Competitive Advantages

  • RNA expression switched on only in target cells

How SRTD Biotech grows

Growth Strategy

Advance the preclinical pipeline to an IND filing.

Regulatory Context

Programmes must complete preclinical development and obtain clinical trial authorisation.

Key Risks

  • Preclinical and clinical risk
  • Insufficient selectivity or toxicity
  • Long regulatory timelines

Strategic Insights

  • The large seed round funds the move from platform to preclinical candidates.
  • Corporate funds from Boehringer Ingelheim and Lilly open the door to future partnerships.

Funding & Investors

Funding Rounds

  • 2026 - Seed: €31,5M
    Lead: Mérieux Equity Partners

Key Investors

Mérieux Equity PartnersNRW.BANKBoehringer Ingelheim Venture FundLilly VenturesHTGFAnobis Asset

Founding Team

Founders

Bernd HoffmannCo-founder & CSO

Key Executives

  • Matthias Alder - CEO

Key Metrics

Stadio della pipelinepreclinico (2026)

Lessons from SRTD Biotech

  • In biotech, capital and industry investors do not replace repeatable data and safety evidence.

Similar Startups

📍 Berlin

HepaRegeniX

Innovative regenerative medicine solutions aimed at curing liver disease and improving patient outcomes.

Read Analysis
📍 Berlin

INVITRIS

Biotechnology company focused on advancing research and development in life sciences and medical technology.

Read Analysis
📍 Berlin

Zedira

Specialised supplier of transglutaminase-related research products and services, catalysing academic and industrial R&D across food science, pharma, and biotech.

Read Analysis

Sources

🎙️ Scalable Podcast — European startup stories · 🇮🇹 in Italian
Spotify 🎧 Apple